Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

788
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
788
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

414
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
414
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

514
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
514
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

584
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
584
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

340
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
340
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

387
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from > 500,000 whole-blood dried blood spot samples.

Lipids in health and disease·2025
Same author

The Use of a Proprietary Near-Infrared Laser to Enhance Wound Healing: A Preliminary Preclinical and Clinical Study.

Aesthetic surgery journal. Open forum·2025
Same author

Overlapping and separable activities of BRA-2 and HIM-17 promote occurrence and regulation of pairing and synapsis during Caenorhabditis elegans meiosis.

Nature communications·2025
Same author

Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants.

Nature microbiology·2024
Same author

<i>Libifem®</i> (<i>Trigonella foenum-graecum</i>) in conjunction with exercise on muscle strength, power, endurance, and body composition in females aged between 25 and 45 years.

Frontiers in sports and active living·2023
Same author

Perspectives on Neuronutrition in Prevention and Treatment of Neurological Disorders.

Nutrients·2023

Related Experiment Video

Updated: Oct 11, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.7K

Palmitoylethanolamide: A Potential Alternative to Cannabidiol.

Paul Clayton1, Silma Subah2, Ruchitha Venkatesh3

  • 1Institute of Food, Brain and Behaviour, Oxford, UK.

Journal of Dietary Supplements
|November 29, 2021
PubMed
Summary

Palmitoylethanolamide (PEA) shows promise as a safe alternative to cannabidiol (CBD) for therapeutic use. PEA offers similar benefits to CBD, including pain relief and neuroprotection, with a better safety profile and regulatory standing.

Keywords:
Side effectscannabidiolefficacyendocannabinoidendocannabinoid modulatorsendocannabinoid systempalmitoylethanolamidepharmacologysafety

More Related Videos

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.4K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.7K

Related Experiment Videos

Last Updated: Oct 11, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.7K
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

6.4K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.7K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • The endocannabinoid system (ECS) regulates homeostasis and is a therapeutic target.
  • Cannabis-derived compounds like THC and CBD interact with the ECS.
  • THC has therapeutic potential but carries risks of toxicity and abuse; CBD offers benefits but lacks sufficient efficacy data and has regulatory ambiguity.

Purpose of the Study:

  • To explore Palmitoylethanolamide (PEA) as a potential alternative to CBD.
  • To highlight PEA's therapeutic properties and safety profile.
  • To address the demand for compounds with similar efficacy to CBD but improved safety and regulatory status.

Main Methods:

  • Literature review and analysis of existing scientific data on PEA and CBD.
  • Comparison of the mechanisms of action, therapeutic effects, and safety profiles of PEA and CBD.
  • Evaluation of PEA's potential based on its interaction with PPAR-α and the ECS.

Main Results:

  • PEA exhibits anti-inflammatory, analgesic, and neuroprotective properties.
  • PEA acts through multiple pathways, including PPAR-α activation and potential ECS modulation.
  • PEA demonstrates a favorable safety and tolerability profile compared to THC.

Conclusions:

  • PEA is a promising alternative to CBD due to its comparable therapeutic effects and superior safety profile.
  • PEA's multi-modal action and established efficacy in various conditions support its therapeutic potential.
  • Further research into PEA formulations may enhance its bioavailability and clinical utility.